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IFN-stimulated genes
ISGsA) has been shown to be active to inhibit the hepatitis B virus gene expression
and replication in transient and stable transfection systems. Here in primary hepatocytes prepared from
naturally woodchuck hepatitis virus (WHV)-infected woodchucks, four siRNAs targeting the WHV preS1, S, C,
and X region led to a depletion of WHV transcripts and replicative intermediates with different kinetics and a
decreased production of viral particles. Two siRNAs targeting WHV S and X region had the highest efﬁcacy to
deplete 70% of WHV transcripts and replicative intermediates. In addition, siRNA-mediated suppression of
WHV enhanced the expression of cellular genes like MxA and MHC I. Speciﬁc siRNAs are able to inhibit the
hepadnaviral replication and enhance the expression of cellular genes relevant for antiviral actions. Thus,
siRNAs might be useful as novel antiviral agents for the treatment of chronic HBV infection.
© 2008 Elsevier Inc. All rights reserved.Introduction
About 350 million people are chronically infected with hepatitis B
virus (HBV) world wide. These patients have a relatively high risk of
developing end-stage liver diseases, such as liver cirrhosis and
hepatocellular carcinoma (Seeger and Mason, 2000). Despite sig-
niﬁcant progress in recent years, the currently available treatment
regiments for hepatitis B such as interferon-α (IFN-α) or nucleoside/
nucleotide analogues are costly and have limited long-term efﬁcacy.
Only about one-third of patients treated with IFN-α show a sustained
response. Nucleoside or nucleotide analogues are not able to eliminate
the virus completely in the vast majority of patients and may select
resistant viral variants during the prolonged treatment (Locarnini and
Mason, 2006; Marcellin, 2002). Therefore, it is necessary to develop
new antiviral strategies against HBV.
RNA interference (RNAi) may provide a promising approach for the
speciﬁc treatment of HBV infection. It is mediated by small interfering
RNAs (siRNAs) of a length of 21 to 23 nucleotides (Hannon, 2002) that
lead to the sequence-speciﬁc degradation of homologous messengerniversity Hospital of Essen,
35929.
l rights reserved.RNAs (mRNAs). Using chemically synthesized or vector-expressed
siRNAs, many clinically relevant viruses including the human
immunodeﬁciency virus, HBV, and hepatitis C virus could be inhibited
in vitro (Randall and Rice, 2004; Stevenson, 2003;Wu and Nandamuri,
2004). A number of recent studies have demonstrated the effective-
ness of speciﬁc siRNAs for inhibiting the HBV gene expression and
viral replication (Giladi et al., 2003; Guo et al., 2005; Hamasaki et al.,
2003; Klein et al., 2003; Konishi et al., 2003; McCaffrey et al., 2003;
Morrissey et al., 2005; Shlomai and Shaul, 2003; Uprichard et al.,
2005; Wu et al., 2005). Yet, RNAi has not been tested in a natural
infection system with a complete viral life cycle so far.
The woodchuck hepatitis virus (WHV) is a member of the family
Hepadnaviridae discovered in 1978 (Summers et al., 1978). WHV
causes acute and chronic infections in woodchucks (Marmota monax)
like HBV in humans. The woodchuck model has been proven to be an
informative model for studies on hepadnaviral infection and patho-
genesis and for evaluation of antiviral drugs (Lu et al., 2007;
Roggendorf and Lu, 2005). In this study, we examined the inhibition
of theWHV gene expression and replication inWHV-infected primary
woodchuck hepatocytes (PWHs) by speciﬁc siRNAs. In addition, we
investigated whether the suppression of viral gene expression
modulates the expression of host genes with antiviral and immuno-
logical functions.
Fig.1. Inhibition of theWHV gene expression by speciﬁc siRNAs. (a) A schematic presentation of the open reading frames on theWHV genome and the sites targeted by siRNAs used in
this study. (b) The ability of the selected siRNAs to knock down the speciﬁcWHV transcripts. HepG2 cells were co-transfected with 20 nM of siRNA and 1 μg of the expression plasmids
for selected targets. The WHV gene transcripts were detected 72 h later by Northern blot. The quantiﬁcation of the signals was performed by using Phosphor-Imager. (c) BHK cells
were co-transfected with 20 nM of siRNA and 1 μg of the expression plasmids for selected targets. WHsAg and WHcAg were detected by immunoﬂuorescence staining with speciﬁc
antibodies. The expression of EGFP was directly examined by ﬂuorescence microscopy. RDLU, relative digital light units.
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siRNAs targeting the WHV preS1, S, C, and X gene inhibit WHV
gene expression
Four siRNAs targeting to theWHV genomewere designed by using
the HiPerformance siRNA Design Algorithm (Fig. 1a). The speciﬁc
inhibitory effect of siRNAs was demonstrated by co-transfection of
siRNAs with the respective expression plasmids forWHpreS1, WHsAg,
WHcAg, andWHxAg-EGFP into HepG2 cells or BHK cells. In the HepG2
cells, expression of the speciﬁc WHV mRNAs was decreased by co-
transfection with the respective siRNAs (Fig. 1b). Two siRNAs siWHs
and siWHx were highly efﬁcient to reduce the speciﬁc mRNAs to 24%
and 27% of the mock control while siWHpreS1 and siWHc had only
moderate effects (Fig. 1b).
Additionally, the inhibitory effects of WHV-speciﬁc siRNAs were
investigated on the protein level by the direct detection of WHV
proteins WHsAg and WHcAg by immunoﬂuorescence staining in BHK
cells. The expression of EGFP by the WHxAg-EGFP fusion construct
was examined by ﬂuorescence microscopy. Consistent with theFig. 2. Inhibition of the WHV gene expression and replication in PWHs by speciﬁc siRNAs. P
siRNA siGFP. The WHV transcripts (a) and replicative intermediates (b) were analyzed on
representative result is shown. The data presented asmeans±standard deviation from three i
S, siWHs; C, siWHc; X, siWHx; N, siGFP as a negative control; RDLU, relative digital light undetection of speciﬁc mRNAs, the WHV proteins expression was
decreased by co-transfection with speciﬁc siRNAs (Fig. 1c).
Speciﬁc siRNAs lead to the depletion of WHV transcripts and replicative
intermediates in PWHs
PWHs from chronically infected woodchucks are uniformly
infected by WHV and contain usually a high steady-state level of
WHV speciﬁc transcripts and replicative intermediates. It has been
shown that there are two major transcripts, 2.1 and 3.7 kb in length
found in the liver samples from chronic WHV-infected woodchucks
(Moroy et al., 1985). The 2.1 kb RNAs correspond to the transcripts for
major WHsAg while the 3.7-kb RNA is involved in the expression of
other viral proteins. It is of interest to examine whether speciﬁc
siRNAs are able to deplete the WHV RNAs and replicative inter-
mediates. PWHs with WHV infection were transfected with speciﬁc
siRNAs or control siRNA, respectively. The levels of WHV transcripts
and WHV DNA were assayed on days 2, 4, and 7 after transfection by
Northern blot and Southern blot, respectively. The reduction of WHV
transcripts by speciﬁc siRNAs was readily detectable on day 2 (Fig. 2a).WHs were transfected with 100 nM of siWHpreS1, siWHs, siWHc, siWHx, or a control
days 2, 4, and 7 post transfection by Northern blot and Southern blot, respectively. A
ndependent Southern blotting analysis were also shown (b lower panel). S1, siWHpreS1;
its.
Fig. 3. Inhibition of the production of WHV viral particles released into the cell culture
supernatants by speciﬁc siRNAs. PWHs were transfected with 100 nM of siWHpreS1,
siWHs, siWHc, siWHx, or a control siRNA siGFP. The copy numbers of WHV progeny
DNA secreted into culture supernatants were determined on days 2, 4, and 7 post
transfection by real-time PCR. ⁎ Compared with mock control, pb0.05; ⁎⁎ compared
with mock control, pb0.01.
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WHV surface proteins. The treatment with siWHpreS1 led to the
reduction of WHV 3.7 kb transcripts while the amount of the 2.1 kb
transcripts remained unchanged, since siWHpreS1 has no target site
on the 2.1 kb transcripts. In addition, both 3.7 and 2.1 kb transcripts
were decreased after the transfection with siWHs and siWHx as well.
The siRNA siWHc was less effective to knock down the WHV
transcripts. The inhibitory effect on WHV-speciﬁc mRNAs reached a
maximum on day 4. The transfection with siWHs and siWHx led to a
reduction of WHV mRNA to 35% and 31%, respectively. The effect of
siRNAs lasted at least until day 7 (also see below).
After transfection with WHV-speciﬁc siRNAs, WHV replicative
intermediates in PWHs decreased with a delay compared with the
kinetics of reduction of WHV mRNAs. This can be explained by the
fact that siRNAs do not act directly on the level of the WHV DNAFig. 4. Suppression and rebound of the WHV replication after a single siRNA transfection. PW
were examined on days 2, 4, 7, 10, and 14 by Southern blot analysis (a). The signals detected
setting the mock transfection control as 100% (b). X, siWHx; C, siWHc.intermediates. The decrease of WHV replicative intermediates was
mainly caused by the reduced formation of new WHV ss DNA from
pregenomic RNAs. Consistently, transfection with two potent siRNAs
siWHs and siWHx reduced the amounts of WHV replicative
intermediates in PWHs to a level of 37% on day 7 as compared
with the mock control (Fig. 2b). The other two siRNAs were less
effective.
Furthermore, the release of viral particles into the culture super-
natants was assessed. WHV DNA in culture supernatants was
extracted and quantiﬁed by real-time PCR. A single transfection of
siWHpreS1, siWHs, and siWHx reduced the WHV DNA levels in the
culture supernatants. A reduction of more than 50% of the WHV DNA
level was measured on day 2 after treatment with siWHs and siWHx
and reached a level of about 90% suppression on the day 4 (Fig. 3). A
repeated transfection of siRNAs 24 h after the ﬁrst transfection could
further enhance the silencing effect and led to a 90% reduction of the
WHV DNA concentration in the cell culture supernatants on day 7
(data not shown).
Single transfection of siRNA has only a transient inhibitory effect on
WHV replication
As siRNAs have only limited stability in cells, the RNAi effect ceases
over time and new transcripts can be produced from WHV cccDNAs
(Bartlett and Davis, 2006). Thus, we examined whether new WHV
replicative intermediates are formed in PWHs treated with speciﬁc
siRNAs. PWHs were transfected with siRNAs and the amounts of WHV
replicative intermediates in PWHs were determined up to day 14 after
transfection. As already shown previously, a single transfection with
siWHx led to a reduction ofWHV replicative intermediates up to day 7
(Fig. 4). However, the level of WHV replicative intermediates in
siWHx-treated PWHs returned gradually to a high level on day 14,
suggesting that the therapeutic use of siRNAs against HBV will face
similar problems with the persistence of cccDNAs as observed during
the treatment with nucleoside analogues.Hs were transfected with 100 nM of siWHx or siWHc. WHV replicative intermediates
in Southern blot were analyzed, and the relative strength of signals was calculated by
Fig. 5. Enhancement of the cellular gene expression in PWHs by silencing of WHV. (a)
PWHs were transfected with 100 nM of siWHpreS1, siWHs, siWHc, siWHx, or a control
siRNA siGFP. The expression levels of MxA and MHC I in siRNAs transfected PWHs were
determined by one-step real-time RT-PCR on day 2 post transfection. (b) Kinetics of the
MxA expression in PWHs upon siRNA transfection. PWHs were left untreated (◊),
transfected with siWHx (□), or control siRNA siGFP (Δ). A repeat transfection of siWHx
(■) and siGFP (▴) was performed on day 7 after the ﬁrst transfection. The expression
levels of MxAwere determined by one-step real-time RT-PCR on days 2, 4, 7, and 10 post
transfection. WHV (+) PWH, PWH with WHV infection; WHV (−) PWH, PWH without
WHV infection; ⁎ Compared with mock control, pb0.05; arrows indicate the time
points of transfection.
Fig. 6. Synergistic effect of siRNAs and ETV on WHV replication. (a) PWHs were treated
with 100 nM of siRNAs, ETV, or a combination of siRNA and ETV for 2 days. (b) PWHs
were pretreated with 100 nM of ETV for 10 days, then transfected with 100 nM of
siRNAs and incubated in normal maintaining medium for further 7 days. The WHV
replicative intermediates and transcripts were analyzed by Southern blot and
Northern blot analysis, respectively. A representative experiment is shown. S1,
siWHpreS1; S, siWHs; C, siWHc; X, siWHx; N, siGFP as a negative control; RDLU,
relative digital light units.
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expression of cellular antiviral proteins
It has been shown that hepadnaviruses may inﬂuence the expres-
sion of IFN-stimulated genes (ISGs) in hepatocytes (Foster et al., 1991;
Twu and Schloemer, 1989; Wu et al., 2007). Thus, suppression of the
WHV gene expression and replication may lead to changes in the
expression of these genes. Therefore, we focused on MxA and MHC I,
ISGs known to be involved in antiviral activities and speciﬁc immune
responses. The expression of MxA and MHC I in siRNA-transfected
PWHs was determined by one-step real-time RT-PCR. siRNAs had no
effect on the MxA and MHC I expression in primary hepatocytes fromnaïve woodchucks (Fig. 5a). By contrast, a signiﬁcant increase of the
MxA and MHC I expression occurred in WHV-infected hepatocytes
after transfection with siWHs and siWHx that effectively reduced the
WHV gene expression (Fig. 5a). siWHc and the control siRNA (siGFP),
however, had no or little effect on MxA and MHC I expression in
WHV-infected primary hepatocytes. The enhanced expression of MxA
and MHC I occurred on the day 2 after transfection with siWHs and
siWHx. However, the MxA expression in siRNA treated hepatocytes
decreased gradually and returned to the base line levels within
10 days (Fig. 5b). Interestingly, a repeated transfection with siWHx
stimulated MxA expression again. The mRNA expression levels of
some other cellular genes were also investigated, accordingly IFN-β,
OAS, IP-10, and TNF-α mRNA were all signiﬁcantly upregulated in
siWHs and siWHx-treated WHV-infected PWHs (data not shown).
These results demonstrated that the silencing of the WHV gene
expression enhances the cellular functions that contribute to the
immunological control of viral infections.
We further examined whether the IFN signaling pathways are
modulated by silencing of WHV replication. Two days post transfec-
tion with siWHx, the STAT-1 expression was elevated in PWHs (data
not shown). However, transfection of siRNAs did not affect the
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Furthermore, Bay11-7082, an NF-kappa B inhibitor did not block the
stimulation of MxA in PWHs (data not shown).
A synergistic action of siRNAs and ETV on the inhibition of
WHV replication
Nucleoside analogues like ETV are effective antivirals to inhibit the
activity of hepadnaviral polymerases and prevent the formation of
viral replicative intermediates (Hadziyannis, 2006). Treatment of
WHV-infected PWHs with ETV at a concentration of 100 nM
signiﬁcantly inhibitedWHV replicationwithin 2 days, while combina-
tion of siWHx and ETV exhibited more potent inhibition on WHV
replication than ETV or siRNA treatment alone (Fig. 6a). Treatment of
PWHs with ETV for 10 days led to a strong reduction of WHV
replicative intermediates to a level below 20% of untreated controls
(Fig. 6b upper panel). The levels of WHV transcripts remained
unchanged by ETV treatment, while the transfection with siRNAs
resulted in a reduction of WHV RNAs (Fig. 6b lower panel). The
inhibitory effect of siRNAs on the WHV replication could be seen after
the discontinuation of ETV treatment. The WHV replication
rebounded signiﬁcantly 7 days after ETV discontinuation but
remained at the low levels if the hepatocytes were treated with
siWHs and siWHx (Fig. 6b upper panel).
Further, we tested whether inhibition of WHV replication by ETV
may have an inﬂuence on the expression of MxA as observed for the
use of WHV-speciﬁc siRNAs. ETV treatment did not lead to induction
of MxA in PWHs (Fig. 7), while their expression was enhanced after
transfection with siWHx but not siWHc. These results indicated that
siRNAs could contribute to the antiviral therapies through different
ways and act synergistically with ETV.
Discussion
In this study, we demonstrated that WHV-speciﬁc siRNAs were
able to reduce the levels of WHV mRNAs in primary hepatocytes
naturally infected with WHV. Four siRNAs targeting the different
regions of the WHV genome were used in this study. The siRNAs
targeting theWHV S and X region had the highest efﬁcacywhile siRNA
against the WHV core region was not effective, probably due to the
inappropriate target sequence. The siRNA to theWHV preS regionwas
able to induce the degradation of the speciﬁc 3.7 kb RNAs, while it was
less potent in suppressing WHV replicative intermediates, compared
to siWHs and siWHx. In addition, our results also indicated that
siRNAs and nucleoside analogues may act synergistically in suppres-
sing WHV replication. The control siRNA had slight unspeciﬁc effects
on WHV replication. However, this effect was not signiﬁcant when
compared with mock control.Fig. 7. TheMxA expression in PWHs after siRNA, ETV, or a combination of siRNA and ETV
treatment. PWHs were left untreated or treated with siRNA, ETV, or a combination of
ETV and siRNA. The expression levels of MxA were determined by one-step real-time
RT-PCR 2 days post transfection.There are some interesting features in the action of effective
siRNAs on WHV-infected PWHs. First, the amounts of WHV RNAs,
replicative intermediates, and WHV DNAs in culture supernatants
changed with different kinetics. The decrease of the levels of WHV-
speciﬁc RNAs was readily measurable on day 2. However, the
depletion of WHV replicative intermediates became visible on day 4,
thus with a delayed kinetics compared to that of WHV transcripts.
Obviously, a pool of WHV replicative intermediates was present in
persistently infected PWHs and needed about more than 2 days to be
depleted. The production of viral particles was decreased on day 2 as
the amounts of WHV RNAs were reduced in PWHs, probably due to
the reduced expression of WHV proteins. Second, the amounts of viral
replicative intermediates returned to base line levels within two
weeks. Two factors determine the kinetics of viral rebound. One factor
is the half-life of siRNAs in PWHs. However, it is difﬁcult to determine
the half-life of siRNA in transfected cells and to correlatewith the RNAi
effects (Chiu and Rana, 2003). The formation of new pregenomic RNAs
from the WHV cccDNA pool in PWHs will determine the ﬁnal steady-
state level of WHV replicative intermediates. Thus, repeated applica-
tions of siRNAs or use of modiﬁed siRNAs with a longer half-life would
be necessary for clinical use.
Furthermore, the knock down of WHV gene transcripts by speciﬁc
siRNAs led to an enhanced expression of cellular genes like MxA and
MHC I, which are related to speciﬁc immune responses and antiviral
functions. An increased expression of MxA and MHC I was only
detected in WHV-infected PWHs but not in naïve PWHs. Thus, we
could exclude that the biochemical properties of siRNAs itself were
responsible for IFN induction. In addition, upregulation of the MxA
and MHC I expression occurred only if the siRNAs were effective to
degradeWHV RNAs. For example, siWHc did not induce an increase of
the MxA and MHC I expression in WHV-infected PWHs, as this siRNA
was inactive. Therefore, the mechanisms leading to the enhanced
cellular gene expression byWHV-speciﬁc siRNAs need to be examined
further. One hypothesis is that the knock down of WHV transcripts
would reduce the amount ofWHV proteins and therefore facilitate the
cellular gene expression. Early reports indicated that HBV polymerase
may inhibit the IFN signaling pathway (Wu et al., 2007). Further, HBV
may counteract the host antiviral effector mechanisms by down-
regulating the IFN-inducible MxA promoter through direct interaction
of precore/core proteins or by inhibiting proteasome activities in an
HBX-dependentmanner (Fernandez et al., 2003; Zhang et al., 2004). In
this context, knock down of the viral gene expression would relief
these inhibitory effects on the cellular gene expression. Another
hypothesis to be investigated is that the induction of the cellular genes
may occur due to the triggering of IFN responses by degradation
products of WHV RNAs during RNAi. It has been reported that a
cleavage of cellular RNAs by RNase L produces small RNAs that are able
to activate IFN-β (Malathi et al., 2007). It should be investigated if a
siRNA-directed RNA degradation would also produce small RNA
fragments and trigger the activation of IFN-β gene. This process
could not yet be examined in woodchuck cells due to lack of
woodchuck speciﬁc reagents. It is noteworthy, however, that an
enhanced expression of MxA and MHC I by siRNA treatment does not
occur in established human hepatoma cell lines with HBV replication
(Meng and Lu, unpublished results). This may be due to the defective
IFN signaling pathways in such hepatoma cells (Stojdl et al., 2000).
However, early publications indicated that some other cell lines may
be suitable for such studies (Bridge et al., 2003; Sledz et al., 2003).
Though the mechanisms leading to the enhanced cellular gene
expression need further studies, this effect itself may facilitate the
immunotherapy and lead to an enhanced antiviral activity in vivo. In
chronically HBV-infected patients, there is a deﬁciency of speciﬁc
cellular responses to HBV proteins (Chisari and Ferrari, 1995;
Rehermann, 2007). The early attempts to stimulate the speciﬁc
cellular responses in such patients by conventional HBV vaccines or
DNA vaccines had only limited effects (Mancini-Bourgine et al., 2004).
Table 1
siRNAs target sequences
Designation Target sequences Locationa WHV gene
siWHpreS1 5′-AGCTCAAACTTTCGAAATCAA-3′ 3279–3299s PreS1
siWHs 5′-ACGACAGTCAATTGCAGACAA-3′ 632–652 S
siWHc 5′-AAGAACAATTATAGTAAATCA-3′ 2263–2283 C
siWHx 5′-AAAGATCAATTATTAACTAAA-3′ 1827–1847 X
siGFP 5′-cggcaagctgaccctgaagttcat-3′
a The positions of the target sequences according to the WHV sequence M19183.
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with antiviral drugs would enhance the effect of therapeutic vaccines,
as an effective antiviral treatment with lamivudine would restore the
cellular immune responses in patients to a limited extent (Boni et al.,
1998, 2001, 2003). A combined treatment with antiviral drugs and
therapeutic vaccines has not yet been successfully tested in clinical
trials (Dahmen et al., 2002; Horiike et al., 2005; Vandepapeliere et al.,
2007). In the woodchuck model, such combined approaches have
shown an improved antiviral effect (Lu et al., 2008; Menne et al.,
2007). An enhancement of cellular IFN responses by siRNA may be
beneﬁcial and is worth future investigation.
Taken together, we demonstrated the potential usefulness and
limitation of siRNAs for inhibition of hepadnaviral gene expression
and replication in naturally WHV infected hepatocytes. The ability of
siRNAs to modulate the cellular gene expression speciﬁcally by
suppression of hepadnaviral gene expression and replication repre-
sents a unique aspect and provides new options for treatment of
chronic HBV infection.
Materials and methods
siRNAs and entecavir (ETV)
Four siRNAs were designed by using the HiPerformance siRNA
Design Algorithm (Qiagen, Düsseldorf, Germany) in combination with
the algorithm described by Reynolds et al. (Reynolds et al., 2004). The
sequences of the siRNAs are given according to the WHV59 genome
sequence (GenBank accession no. M19183). The selected siRNAs,
designated as siWHpreS1, siWHs, siWHc, and siWHx, have the speciﬁc
target sequences within the WHV preS1, S, C, and X gene, respectively
(Fig.1 and Table 1). siGFP, a siRNA against green ﬂuorescent protein, was
used as the control (Table 1). All siRNAs were purchased from Qiagen.
ETV was purchased from Bristol-Myers Squibb (Munich, Germany).
Woodchucks
All animals were purchased from North Eastern Wildlife (Ithaca,
NY, USA) and kept in the center of animal laboratory of the University
of Essen. Experiments were conducted in accordance with the GuideTable 2
Primers used for ampliﬁcation of WHV preS1, X, and C gene and real-time RT-PCR assay
Amplicon Primer Polarity Nuc
WHV preS1 whpres1 Sense 5′-C
whs2 Antisense 5′-C
WHV X gene whx-1 Sense 5′-A
whx-2 Antisense 5′-T
WHV C gene wc1 Sense 5′-T
wc-149s Antisense 5′-A
Woodchuck β-actin wβ-actin-A1 Sense 5′-T
wβ-actin-A2 Antisense 5′-T
Woodchuck MHC I wMHCI-s1 Sense 5′-C
wMHCI-a1 Antisense 5′-G
Woodchuck MxA wMxA-s1 Sense 5′-G
wMxA-a1 Antisense 5′-C
The underlined part of primer wc-149s indicates the speciﬁc cleavage sites of restriction enfor the Care and Use of Laboratory Animals and were reviewed and
approved by the local Animal Care and Use Committee of the district
government (Düsseldorf, Germany).
Primary hepatocytes culture and siRNA transfection
Primary hepatocytes from WHV-infected and uninfected wood-
chucks were prepared by liver perfusion with collagenase IV (Sigma,
Munich, Germany) as described previously (Baccarani et al., 2003).
The viability of prepared hepatocytes was assessed by trypane blue
dye exclusion and exceeded 80% in all experiments. The cells were
plated at a density of 1.5×106 cells per well on collagen I-coated six-
well plates in Williams medium (Gibco, Karlsruhe, Germany)
supplemented with 10% fetal calf serum (Gibco), 1 mg/ml of
hydrocotisone (Sigma), 10 μg/ml of insulin (Serva, Amsterdam, The
Netherlands), 50 μg/ml of gentamycin (Sigma), 50 IU/ml of penicillin–
streptomycin (Gibco), 2 mM glutamine (Gibco), 1.25 mg/ml of inosine
(Serva), and 1% DMSO (Merck, Darmstadt Germany).
Transfection of primary hepatocytes with siRNAs was carried out
on day 2 of in vitro culture except speciﬁcation. Lipofectamine 2000
(Invitrogen, Karlsruhe, Germany) was used according to the manufac-
turer's instructions. 150 pmol siRNA and 5 μl of Lipofectamine 2000
per well were applied in a ﬁnal volume of 1.5 ml Opti-MEM. After 5 h,
the medium was replaced by fresh culture medium.
To ensurehighlyefﬁcient siRNAdelivery intohard-to-transfect PWHs,
a high amount of siRNA is needed (Gilot et al., 2005). A dose-ﬁnding
experiment suggested that siWHx inhibited the WHV gene expression
and replication in a dose-dependent manner. 100 nM of siRNAs were
used in the present experiments. Although higher concentration than
100 nM led to more potent effect on the mRNA level, no more reduction
on WHV replication was observed (data not shown).
Construction of expression vectors for WHV preS1, surface antigen
(WHsAg), core protein (WHcAg), and X protein (WHxAg)-enhanced
green ﬂuorescent protein (EGFP) fusion
The plasmids expressing WHsAg and WHcAg were described
previously (Lu et al., 1999). To construct the vector expressing the
WHV preS1 protein, the WHV genome region (nt 2992–964) was
ampliﬁed by PCR with the primers whpres1 and whs2 (Table 2) and
cloned into the pCR2.1 vector (Invitrogen). The fragment containing
the large WHsAg gene was isolated by digestion with EcoRI and
inserted into the EcoRI site of the pcDNA3 vector (Invitrogen). The
generated plasmid contained the large WHsAg gene under the control
of the cytomegalovirus promoter. The region comprising the WHV X
region was ampliﬁed with the primers whx-1 and whx-2 (Table 2),
and cloned into the pCR2.1 vector. The clone sequence was veriﬁed by
DNA sequencing. The fragment containing the WHV X region was cut
by EcoRI and cloned into the EcoRI site of pIRES2-EGFP vector
(Clontech, Heidelberg, Germany).leotide sequence Position Reference
AGCTAGTGCAACATAATGG-3′ 2976 M19183
CACCATTTTGTTTTATTGA-3′ 987 M19183
TGGCTGCTCGCCTGTGTTGC-3′ 1503 M19183
TACAGAAGTCGCATGCATTT-3′ 1928 M19183
GGGGCATGGACATAGATCCCTA-3′ 2015 M19183
AGATCTCTAAATGACTGTATGTTCCG-3′ 2467 M19183
GGAATCCTGTGGCATCCATGAAAC-3′ 1 AY170121.1
AAAACGCAGCTCAGTAACAGTCCG-3′ 349 AY170121.1
CAGACCCAGGAGATGGAAC-3′ 729 AF146091
GACAATCACAGCAGCAACA-3′ 940 AF146091
GAGGGAGGAGAAGAGGAAA-3′ 66 EU503128
TGGAGATGCGGTTGTGAG-3′ 189 EU503128
zyme BglII.
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Culturing and transfection of BHK and HepG2 cells were carried
out as described previously (Zheng et al., 2002). To detect WHsAg
and WHcAg, immunoﬂuorescence staining was performed with
monoclonal mouse anti-WHpreS (Waters et al., 2001; Zheng et al.,
2002) or anti-WHcAg antibodies (Zhang et al., 2006). The anti-
WHpreS antibody recognizes the middle WHsAg that contains the
major WHsAg as a domain. The expression of EGFP by the WHx-
EGFP fusion was determined by direct observation and photography
under a ﬂuorescence microscope with an excitation wavelength of
490 nm.
Isolation and analysis of viral RNA and WHV replicative intermediates
Total RNA was extracted from hepatocytes with TRIzol reagent
(Invitrogen) according to the manufacturer's instructions. Northern
blot analysis was carried out by agarose-glyoxal method according to
published protocols (Meng et al., 2008). WHV replicative intermedi-
ates were puriﬁed from intracellular core particles according to the
protocol described for HBV previously (Meng et al., 2008). The isolated
WHV DNA was subjected to agarose gel electrophoresis, followed by
denaturation and Southern blotting. WHV RNA and DNA on Northern
and Southern blots were detected by hybridization with a 32P-labeled
full length HBV probe. The quantitative analysis of the signals on the
Southern blots and Northern blotswas performed by using a Phospho-
Imager (Cyclon, Parkard, Meriden, CT, USA). The total WHV replicative
intermediates shown as a smear in the Southern blots including the
three major forms: RC (relaxed circular), DL (duplex linear), and SS
(single-stranded) DNAwere quantiﬁed. The relative strength of signals
(relative digital light units, RDLU) was calculated by setting the mock
transfection control as 100%. The WHV speciﬁc gene transcripts in
cotransfection experiments and the 3.7 and 2.1 kb RNAs in PWHswere
quantiﬁed and normalized against β-actin. The RDLU was calculated
by setting the mock transfection control as 100%.
Quantitation of WHV progeny DNA in culture supernatants
WHV progeny DNA in the culture supernatants was extracted
using Qiaamp DNA blood mini kit (Qiagen) and quantiﬁed as genome
equivalents (GE) per ml by real-time PCRwith LightCycler DNAmaster
SYBR green kit (Roche Diagnostics, Mannheim, Germany). PCR was
performed with the primers wc1 and wc-149s (Table 2) (Lu et al.,
2005, 2008) on Light Cycler™ instrument (Roche) with 95 °C for 0 s,
53 °C for 10 s and 72 °C for 12 s. A plasmid containing a full length
WHV genome was diluted and served as standard. The detection limit
of this assay was 103 WHV GE/μl.
Real-time reverse-transcriptase (RT) PCR
Total RNA was puriﬁed using the RNeasy Mini Kit (Qiagen)
according to the manufacturer's instructions. One-step real-time RT-
PCR was performed with 100 ng of total RNA using QuantiFast SYBR
Green RT-PCR Kit (Qiagen) on a Light Cycler™ instrument (Roche)
with 50 °C for 10min for reverse transcription followed by 45 cycles of
PCR: 95 °C 10 s, 60 °C 30 s. The primers used are listed in Table 2. The
relative mRNA copies were determined with a standard curve
constructed using corresponding cDNA fragments. The copy numbers
of woodchuck MxA and MHC I transcripts were normalized against
woodchuck β-actin transcripts.
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